



**SDI Review Form 1.6**

Journal Name:	<a href="#">European Journal of Medicinal Plants</a>
Manuscript Number:	<b>Ms_EJMP_23992</b>
Title of the Manuscript:	<b>The role of monocarboxylate transporters and their chaperone CD147 in lactate efflux inhibition and the anticancer effects of Terminalia chebula in neuroblastoma cell line N2-A</b>
Type of the Article	<b>Original Research Article</b>

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p>The manuscript is prepared with a great care, is complete and logical.</p> <p>Please explain the usage of chosen cell lines. In which tests DI-TNC1 line was? It would be valuable to use more than 1 cancer cells line</p> <p>Please explain what was the basis of choosing the concentrations of TCE for different tests.</p> <p>Please add the description of control cells in every experiment.</p> <p>What was the concentration of FBS in the experimental media in different tests?</p>	<p><b>Used Cell lines</b></p> <p><u>Cell Culture</u></p> <p><u>N2A is known for its high lactate production rate compared to other cell lines. It is considered an appropriate model to evaluate potential chemotherapy drugs for the treatment of cancer (Finklestein et al., 1975; Klebe and Ruddie, 1969; Mazzio et al., 2003)</u></p> <p><u>DI-TNC1 are astrocyte proliferative cell line with lower lactate efflux production compared to N2A cells, -an observation in our lab-, both cell lines used are constituents of the central nervous system. The system. The DI-TNC is very important in important in controlling brain energy metabolism (Magistretti and Pellerin, 1999; -, Pellerin et al., 1997)</u></p> <p><u>N2A is appropriate model to evaluate potential chemotherapy drugs for the treatment of cancer (Finklestein et al., 1975; Klebe and Ruddie, 1969; Mazzio et al., 2003)</u></p> <p><u>DI-TNC1 cell line is very essential constituents of the central nervous system and it is very important in controlling brain energy metabolism (Magistretti and Pellerin, 1999; -, Pellerin et al., 1997)</u> [N1]</p> <p><b>More cell Lines</b></p>



SDI Review Form 1.6

		<p><del>I</del>We agree with you <del>and there is another part of this paper [N2] and that it will be a great avenue for</del> future work <del>will to</del> address the effects of the <u>TNC</u> plant component on different <u>human</u> cell lines <u>with a high rate of lactate production character</u>.</p> <p><b>TCE Concentrations</b>  <u>For lactate efflux inhibition and viability studies studies. The the</u> chosen concentrations were based on different preliminary studies in <u>our the lab, and the authors did not want to over explain all the details.</u>  <u>Based on the dose -response study of viability, Western blot and caspase studies were conducted at small concentration (0-5 µg/ml) to keep the cells alive and measure the changes in protein expression and caspase 3.</u></p> <p><u>Growth inhibition studies were applied at a concentration range that does not kill the cells but affect their normal growth rate.</u></p> <p><b>Control Cells</b>  <del>I did add the the</del> <u>description of the control cells were described as follows: We revised with yellow highlight. Please check the manuscript.</u></p> <p><b>FBS Concentrations</b>  Growth study was conducted with phenol-free media supplemented with 10% FBS and 1% penicillin/streptomycin. For all other experiments we used phenol-free media supplemented with 1% each FBS/penicillin/streptomycin.</p>
--	--	--



**SDI Review Form 1.6**

<p><b><u>Minor</u></b> REVISION comments</p>	<p>Line 105; please explain the abbreviation</p> <p>Fig. 1; please add the levels on the diagram</p> <p>Fig. 3 and 6; I would reorganize the figure, part A left, part B right side</p> <p>Fig. 5; for the reviewer the picture B is completely illegible, please replace it with better one. I would choose better magnification.</p> <p>Line 75-76, please add the description of antibodies</p>	<p>We <del>did with yellow highlight</del>highlighted the <del>explanationrevision</del>explanation in yellow. Please see revised manuscript.</p> <p>We did-The levels were added on the diagram</p> <p>Yes, it sounds better but our concern is the size of the Figures. it will be too small. We feel like the size of the figures will be too small if we have it like that.</p> <p>We fixed [N3]</p> <p>We replaced the merged pictures. Please see revised manuscript</p> <p>We revised and added the discription as suggested.</p>
<p><b><u>Optional/General</u></b> comments</p>		